Abstract
The frequency with which polyneuropathy developed was investigated in patients with cancer of the larynx and pharynx who participated in a double-blind trial of the radiosensitizing drug misonidazole. Fourteen of 36 patients receiving misonidazole (total dose of about 11 g/m2) developed neuropathy, while this occurred in only 2 of 34 patients in the placebo group.
Vibration perception threshold increased in all patients who developed neuropathy, but also in 12 (5 misonidazole and 7 placebo treated) without other symptoms or signs of neuropathy.
Pharmacokinetic studies of misonidazole revealed a correlation between development of neuropathy and a high ‘peak plasma concentration/g misonidazole in each fraction’ and especially a high ‘area under plasma concentration curve/g misonidazole in each fraction’.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dische S: The neurotoxicity of misonidazole: Pooling of data from five centres. Br J Radiol 51:1023–1024, 1978
Adams GE: MRC randomized studies of misonidazole in combination with radiotherapy. Br J Radiol 55:464–465, 1982
Kogelnik HD: Clinical experience with misonidazole. High dose fractions versus daily low doses. Cancer Clin Trials 3:179–186, 1980
Saunders MI, Dische S, Anderson P, Flockhart IR: The neurotoxicity of misonidazole and its relationship to dose, halflife and concentration in the serum. Br J Cancer 37, Suppl III:268–270, 1978
Urtasun RC, Chapman JD, Feldstein ML, Band RP, Rabin HR, Wilson AF, Marynowski B, Starreveld E, Shnitka T: Peripheral neuropathy related to misonidazole: Br J Cancer 37, Suppl III:271–275, 1978
Wasserman TH, Stetz J, Phillips TL: Radiation therapy oncology group clinical trials with misonidazole. Cancer 47:2382–2390, 1981
Overgaard J, Andersen AP, Jensen RH, Hjelm-Hansen M, Jørgensen K, Petersen M, Sandberg E, Sand Hansen H: Misonidazole combined with splitcourse radiotherapy in the treatment of invasive carcinoma of the larynx and the pharynx. A preliminary report of the Danish Head and Neck Cancer Study (DAHANCA) protocol 2. Acta Otolaryngol, Suppl 386:215–220, 1982
Melgaard B, Sand Hansen H, Kamieniecka Z, Paulson OB, Gersel Pedersen A, Tang X, Trojaborg W: Misonidazole neuropathy: Ann Neurol 12:10–17, 1982
Overgaard J, Overgaard M, Nielsen OS, Kirstein Pedersen Thimoty AR: A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br J Cancer 46:904–911, 1982
Overgaard J, Overgaard M, Timoty AR: Studies of the pharmacokinetic properties of nimorazole. Br J Cancer 48:27–34, 1983
Nielsen VK: The peripheral nerve function in chronic renal failure. Acta Med Scan 191:287–296, 1972
Urtasun RL, Tanasichuk H, Fulton D, Agboola O, Turner AR, Koziol D, Raleigh J: High-dose misonidazole dexamethasone rescue: A possible approach to circumvent neurotoxicity. Int J Radiation Oncology Biol Phys 8:365–368, 1982
Moore JL, Paterson ICM, Dawes PJDK, Henk JM: Misonidazole in patients receiving radical radiotherapy: Pharmacokinetic effects of phenytoin, tumour response and neurotoxicity. Int J Radiation Oncology Biol Phys 8:361–364, 1983
Overgaard J, Sand Hansen H, Andersen AP, Hjelm-Hansen M, Jørgensen K, Sandberg E, Rygård J, Jensen RH, Pedersen M: Misonidazole as an adjuvant to radiotherapy in the treatment of invasive carcinoma of the larynx and the pharynx. 2nd Interim analysis of the Danish Head and Neck Cancer study (DAHANCA) — protocol 2. In: Kärcher KH et al. (eds): Progress in Radio-Oncology III, ICRO, Vienna, pp 137–147, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Melgaard, B., Køhler, O., Hansen, H.S. et al. Misonidazole neuropathy A prospective study . J Neuro-Oncol 6, 227–230 (1988). https://doi.org/10.1007/BF00163705
Issue Date:
DOI: https://doi.org/10.1007/BF00163705